Roche is building labs where the AI runs the experiments
Two moves in the same 24 hours, pointing in opposite directions: a pharma giant starts rebuilding its research labs around machines that run their own experiments, and Beijing extends its grip on the people who build AI.
Roche said at its pharma investor day on Monday that it has started building autonomous AI-driven laboratories, under a model it calls "lab-in-the-loop" — AI models propose the experiments, automated systems run them, and the results feed back into the models. Aviv Regev, executive vice president of Genentech Research and Early Development, framed the push as "AI independence" in R&D, and the loop spans the whole pipeline, from target discovery and lead identification through optimisation to the clinic. Roche's own investor deck lays out an autonomy ladder from a 2026 preprint by Cheng and co-authors: L0 is fully manual, L1 automated instruments, L2 connected workflows, L3 AI-assisted workflows, L4 domain autonomy, L5 lab-wide autonomy. An "Autonomous Lab Accelerator" is the vehicle driving it, and Roche still defines four human roles at every rung — operator, assistant, approver, auditor.
The money is the part that says how seriously to take it. Roche is reallocating CHF 1,958 million — about $2.41 billion — of R&D savings from 2024 to 2026, and "future capabilities (e.g. lab-in-the-loop, organoids)" is one of the three named buckets it goes into. Regev said 40% of pipeline decisions from the fourth quarter of 2025 through the second quarter of 2026 had a tracked AI or computational contribution, 44% in that most recent quarter, and Roche says its TargetNexus agent is on track to be part of 80% of research portfolio decisions by the end of 2026. The company also reported its Phase III success rate rising to more than 80% so far in 2026 from 65% in 2025 — a number worth treating as pipeline luck and process changes working together, not an AI result on its own.
Read it as the first concrete autonomy spec from a top-five pharma, not as a launch. Roche put numbers on the ladder and the coverage targets, but disclosed no capital figure, no lab count and no named automation partners for the labs themselves, so the build-out is direction rather than commitment. One number in the Cailianpress write-up of the day needs correcting: the "up to 20 new molecular entities by 2030" target is Roche's standing ambition from its September 2024 investor day, restated Monday — new framing on an old goal, not a new promise. The related real estate is real, though: Roche opened its Boston Innovation Center on 17 September, 95,000 square feet with capacity for up to 500 people, part of a $50 billion US commitment, and it will partly focus on AI and machine learning in drug development.
Bloomberg reported on Monday that China has widened its overseas travel restrictions on top AI and chip executives to cover their families — spouses and children now need Beijing's approval to go abroad, even for short trips. The people covered include prominent startup founders and heads of strategically important AI companies whose work is judged vital to state security, and government departments have already begun notifying affected individuals, according to people familiar with the matter. It is not an outright travel ban, it is unclear whether every family of someone already under the curbs is covered, and Beijing plans to add more individuals over time; the Ministry of Industry and Information Technology did not respond to a request for comment.
The rule extends curbs Bloomberg reported in May on private-sector AI staff at companies including Alibaba and DeepSeek, and it sits alongside a separate instrument now in force: exit-ban enforcement rules that took effect on 15 September, which Human Rights Watch has documented as State Council Decree No. 841 — allowing exit bans of up to three years for conduct that may endanger national industrial or technological security. Two cautions before you treat the family measure as settled policy. It is single-origin reporting from anonymous sources with no government document published, no agency named, and no independent newsroom confirmation so far; the on-the-record part of this story is the decree, not the family rule. Frame the rest as "reportedly," because Beijing has not confirmed it.
What to watch: whether Roche ever puts capex, a lab count or partners against the autonomous-lab push — the direction is clear, the bill is not — and whether any outlet beyond Bloomberg independently confirms the family travel rule.
If a lab can propose and run its own experiments, is the scientist the approver or just the bottleneck? Tell us in the comments.
Sources: Roche — Pharma Day 2026 deck · Roche investor event · Reuters via CNA · SWI swissinfo.ch · Cailianpress (财联社) · Bloomberg · Business Standard — Bloomberg wire · The Next Web · The Standard · Lianhe Zaobao · Human Rights Watch — Decree No. 841
